# A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

> **NCT04899310** · PHASE1,PHASE2 · TERMINATED · sponsor: **ModernaTX, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Methylmalonic Acidemia

## Interventions

- **BIOLOGICAL:** mRNA-3705
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04899310
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-06
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** As part of ongoing efforts to refine the MMA program strategy, we are reevaluating clinical study plans for mRNA-3705, in order to further optimize the development program. As part of this process, Moderna will be closing the mRNA-3705-P101 study.
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04899310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04899310, "A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04899310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*